Another small molecule SBI-0640756 (SBI-756), a first-in-class inhibitor that targets EIF4G1 and disrupts the EIF4F complex, can effectively inhibit the growth of NRAS, BRAF, and NF1-mutant melanomas in vitro and delay the onset and reduce the incidence of Nras/Ink4a melanomas in vivo [40]. The gene discussed is CDKN2A; the disease is melanoma.